Literature DB >> 9755890

Permeability characteristics of tetragastrins across intestinal membranes using the Caco-2 monolayer system: comparison between acylation and application of protease inhibitors.

T Fujita1, I Kawahara, Y Quan, K Hattori, K Takenaka, S Muranishi, A Yamamoto.   

Abstract

PURPOSE: Three types of acyl tetragastrin (TG), acetyl-TG (C2-TG), butyryl-TG (C4-TG) and caproyl-TG (C6-TG) were synthesized and their in vitro intestinal permeability characteristics were examined using Caco-2 monolayers.
METHODS: The disappearance of acyl-TGs from the apical side of Caco-2 monolayers was estimated by analyzing degradation and permeation processes in terms of clearance.
RESULTS: The amount of native TG transported to the basolateral side was very low due to its large degradation clearance (CLd) on the apical side. Degradation of TG was reduced by chemical modification with fatty acids, which resulted in an increase in the transport of TG across Caco-2 monolayers. In addition, the permeation clearance (CLp) value of carboxyfluorescein (CF), a paracellular transport and undegradable marker, was increased in the presence of acyl-TGs. Furthermore, we investigated the effects of the protease inhibitors bacitracin and gabexate on the transport of TG across Caco-2 monolayers. In the presence of a low concentration (0.1 mM) of protease inhibitor, the CLd value of TG was reduced, but they did not affect its CLp value. However, a higher concentration (1.0 mM) of bacitracin significantly reduced TG degradation on the apical side, and further increased its CLp value.
CONCLUSIONS: We demonstrated that acylation of TG made it resistant to intestinal proteases and caused it to enhance absorption of drugs, including itself, across Caco-2 monolayers. Further, bacitracin acted as both a protease inhibitor and an absorption enhancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9755890     DOI: 10.1023/a:1011997404306

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  16 in total

1.  A survey of membrane peptidases in two human colonic cell lines, Caco-2 and HT-29.

Authors:  S Howell; A J Kenny; A J Turner
Journal:  Biochem J       Date:  1992-06-01       Impact factor: 3.857

2.  Effects of proteolytic enzyme inhibitors on the nasal absorption of vasopressin and an analogue.

Authors:  K Morimoto; H Yamaguchi; Y Iwakura; M Miyazaki; E Nakatani; T Iwamoto; Y Ohashi; Y Nakai
Journal:  Pharm Res       Date:  1991-09       Impact factor: 4.200

Review 3.  The use of cultured epithelial and endothelial cells for drug transport and metabolism studies.

Authors:  K L Audus; R L Bartel; I J Hidalgo; R T Borchardt
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

4.  Enzymatic degradation of C-terminal tetrapeptide amide of gastrin by mammalian tissue extracts.

Authors:  L Laster; J H Walsh
Journal:  Fed Proc       Date:  1968 Nov-Dec

5.  Structure-function relationships in the active C-terminal tetrapeptide sequence of gastrin.

Authors:  J S Morley; H J Tracy; R A Gregory
Journal:  Nature       Date:  1965-09-25       Impact factor: 49.962

6.  Effects of protease inhibitors on the absorption of phenol red and fluorescein isothiocyanate dextrans from the rat intestine.

Authors:  S Gotoh; R Nakamura; M Nishiyama; Y S Quan; T Fujita; A Yamamoto; S Muranishi
Journal:  J Pharm Sci       Date:  1996-08       Impact factor: 3.534

7.  Development of new lipophilic derivatives of tetragastrin: physicochemical characteristics and intestinal absorption of acyl-tetragastrin derivatives in rats.

Authors:  T Tenma; E Yodoya; S Tashima; T Fujita; M Murakami; A Yamamoto; S Muranishi
Journal:  Pharm Res       Date:  1993-10       Impact factor: 4.200

8.  Improvement of transdermal delivery of tetragastrin by lipophilic modification with fatty acids.

Authors:  K Setoh; M Murakami; N Araki; T Fujita; A Yamamoto; S Muranishi
Journal:  J Pharm Pharmacol       Date:  1995-10       Impact factor: 3.765

9.  Gastrointestinal absorption of peptide drug: quantitative evaluation of the degradation and the permeation of metkephamid in rat small intestine.

Authors:  Y Taki; T Sakane; T Nadai; H Sezaki; G L Amidon; P Langguth; S Yamashita
Journal:  J Pharmacol Exp Ther       Date:  1995-07       Impact factor: 4.030

10.  Enhanced bioavailability of subcutaneously injected insulin by pretreatment with ointment containing protease inhibitors.

Authors:  M Takeyama; T Ishida; N Kokubu; F Komada; S Iwakawa; K Okumura; R Hori
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

View more
  6 in total

1.  Development of novel lipophilic derivatives of DADLE (leucine enkephalin analogue): intestinal permeability characateristics of DADLE derivatives in rats.

Authors:  T Uchiyama; A Kotani; H Tatsumi; T Kishida; A Okamoto; N Okada; M Murakami; T Fujita; Y Fujiwara; Y Kiso; S Muranishi; A Yamamoto
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

2.  Position of lipidation influences anticancer activity of Smac analogs.

Authors:  Ewa D Micewicz; Christine Nguyen; Alina Micewicz; Alan J Waring; William H McBride; Piotr Ruchala
Journal:  Bioorg Med Chem Lett       Date:  2019-04-26       Impact factor: 2.823

3.  Lipid-conjugated Smac analogues.

Authors:  Ewa D Micewicz; Josephine A Ratikan; Alan J Waring; Julian P Whitelegge; William H McBride; Piotr Ruchala
Journal:  Bioorg Med Chem Lett       Date:  2015-09-08       Impact factor: 2.823

Review 4.  Fatty acids as therapeutic auxiliaries for oral and parenteral formulations.

Authors:  Michael J Hackett; Jennica L Zaro; Wei-Chiang Shen; Patrick C Guley; Moo J Cho
Journal:  Adv Drug Deliv Rev       Date:  2012-08-17       Impact factor: 15.470

5.  A two-step strategy to enhance activity of low potency peptides.

Authors:  Jamie R Doyle; Benjamin N Harwood; Subrahmanian Tarakkad Krishnaji; Vijay M Krishnamurthy; Wei-En Lin; Jean-Philippe Fortin; Krishna Kumar; Alan S Kopin
Journal:  PLoS One       Date:  2014-11-12       Impact factor: 3.240

Review 6.  Peptide Lipidation - A Synthetic Strategy to Afford Peptide Based Therapeutics.

Authors:  Renata Kowalczyk; Paul W R Harris; Geoffrey M Williams; Sung-Hyun Yang; Margaret A Brimble
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.